Related Experiment Video
Updated: Aug 24, 2025

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Acute Ischemic Stroke and Heart Failure: Stroke Risk Factors Associated with Exclusion from Thrombolytic Therapy
Carolyn Breauna Sanders1, Krista Knisely1, Chase Rathfoot1
1368074School of Medicine Greenville, University of South Carolina, Greenville, SC, USA.
Insights
Older patients with heart failure experiencing acute ischemic stroke are less likely to receive recombinant tissue plasminogen activator (rtPA) therapy due to factors like coronary artery disease and elevated INR. Developing targeted strategies can improve rtPA eligibility for these patients.
Area of Science:
- Neurology
- Cardiology
- Stroke Medicine
Background:
- Acute ischemic stroke (AIS) patients with congestive heart failure (HF) often have risk factors complicating treatment.
- Recombinant tissue plasminogen activator (rtPA) is a critical treatment for AIS, but its use in AIS-HF patients is less understood.
- Identifying specific risk factors for rtPA exclusion in AIS-HF patients is crucial for optimizing care.
Purpose of the Study:
- To identify the risk factors associated with the exclusion of AIS patients with HF from rtPA therapy.
- To analyze the characteristics of AIS-HF patients who receive or do not receive rtPA.
Main Methods:
- Retrospective analysis of 5469 AIS patients (590 with HF) from a regional stroke registry (2010-2016).
- Logistic regression analysis was used to determine risk factors for rtPA exclusion in AIS-HF patients.
- Evaluation of baseline risk factors including age, coronary artery disease, and INR.
Main Results:
- Older age (OR=0.982), coronary artery disease (OR=0.618), and elevated INR (OR=0.326) were associated with rtPA exclusion in AIS-HF patients.
- AIS-HF patients receiving rtPA were more likely to show improved ambulatory status (OR=1.69).
- The model demonstrated strong discriminating power with an AUROC of 0.668.
Conclusions:
- Specific risk factors, including advanced age, coronary artery disease, and elevated INR, are linked to rtPA exclusion in AIS-HF patients.
- These findings highlight the need for tailored management strategies to enhance rtPA eligibility for older HF patients.
- Developing targeted interventions can improve treatment outcomes for AIS-HF patients.
Abstract:
Objective: Acute ischemic stroke (AIS) patients with congestive heart failure (HF) that present with various risk factors are less likely to receive recombinant tissue plasminogen activator (rtPA). The risk factors associated with excluding AIS patients with congestive heart failure (AIS-HF) from rtPA therapy have not been fully established. Methods: Retrospective data for 5469 AIS patients comprised of 590 AIS patients with HF and 4879 AIS patients without HF were collected from a regional stroke registry between January 2010 and June 2016. Baseline risk factors were analyzed using logistic regression analysis to determine the risk factors associated with rtPA exclusion in AIS-HF patients. Results: In the adjusted analysis, AIS-HF patients that that did not receive rtPA were more likely to be older (OR = 0.982, 95% CI, 0.966-1, P = .020), presented with coronary artery disease (OR = 0.618, 95% CI, 0.391-0.98, P = .040), and with an elevated INR (OR = 0.326, 95% CI, 0.129-0.82, P = .018). AIS-HF patients that were included for rtPA therapy were more likely to show improvement in ambulatory status (OR = 1.69, 95% CI, 1.058-2.7, P = .028). The discriminating power of the model was strong with an area under the curve (AUROC) = 0.668 (95% CI, 0.611-0.724, P < .001). Conclusion: Our study establishes the associations between stroke risk factors and exclusion from rtPA therapy. This finding suggests the need to develop management strategies for older HF patients with carotid artery disease and an elevated INR to improve their eligibility for rtPA treatment following an acute ischemic stroke.
More Related Videos
Related Concept Videos
Heart Failure I: Introduction
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Heart Failure IV: Classification and Diagnostic Evaluation
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Heart Failure VI: Adjunct Therapies

